Evommune (EVMN) Return on Sales (2025 - 2026)
Evommune (EVMN) reported Return on Sales of 0.06% for Q1 2026, down 1.0% year-over-year from 0.06% in Q1 2025, and down 1.25% on a QoQ basis from 0.06% in Q4 2025.
Evommune (EVMN) has 2 years of Return on Sales data on file, last reported at 0.06% in Q1 2026.
- Quarterly Return on Sales fell 1.0% year-over-year to 0.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.06% (changed N/A YoY) and the FY2025 annual result came in at 0.06%, up 4.0% from the prior year.
- Return on Sales declined to 0.06% in Q1 2026 per EVMN's latest filing, from 0.06% in the prior quarter.
- Across five years, Return on Sales topped out at 0.01% in Q3 2025 and bottomed at 0.06% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.00% |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | -0.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.06% |
| Dec 31, 2025 | -0.06% |
| Sep 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.05% |